New drug namilumab tested for lung sarcoidosis – but trial halted early
Disease control
Terminated
This study tested namilumab, an experimental drug, in 107 people with chronic pulmonary sarcoidosis, a condition causing lung inflammation. The trial was randomized and placebo-controlled, but it was terminated early. The goal was to see if namilumab could reduce the need for res…
Phase: PHASE2 • Sponsor: Kinevant Sciences GmbH • Aim: Disease control
Last updated Jun 26, 2026 15:32 UTC